A sign for the Food and Drug Administration is displayed outside their offices in Silver Spring, Md., on Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File)
U.S. health officials are alerting consumers about two more recalls of eyedrops due to contamination risks that could lead to vision problems and serious injury.
The announcements follow a recall last month of eyedrops made in India that were linked to an outbreak of drug-resistant infections. One person died and at least five others had permanent vision loss.
There's no indication the latest recalls are related to those products.
The Food and Drug Administration posted separate recall notices for certain eyedrops distributed by Pharmedica and Apotex after the companies said they are voluntarily pulling several lots of their products from the market. Both companies said the recalls were conducted in consultation with the FDA.
Pharmedica on Friday said it is recalling two lots of Purely Soothing 15% MSM Drops due to problems “that could result in blindness." The over-the-counter drops are designed to treat eye irritation. The Phoenix-based company said consumers should immediately stop using the drops and return them to the place they were purchased.
The recall affects nearly 2,900 bottles, according to the company. The drops were manufactured in Arizona.
Last week, the FDA posted a separate recall announcement from Apotex recalling six lots of prescription eyedrops used to treat a form of glaucoma. The company said it launched the recall after finding cracks in a handful of bottle caps.
The drops are distributed as Brimonidine Tartrate Ophthalmic Solution. 0.15% and were sold between last April through February.
Apotex said in an email that the eyedrops were manufactured in Canada. The company hasn't received any reports of injuries related to the drops.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Countries around the world continue to grapple with rising COVID cases, with Germany confirming case numbers at their highest at any point during the pandemic. German officials say that 48,000 new cases are being reported everyday.
Jill and Carlo cover the developing story out of suburban Milwaukee, where a speeding SUV careened through a Christmas parade. Looters get more brazen in San Francisco, the missing Chinese tennis star resurfaces, and more.
A CDC panel has unanimously endorsed boosters of the Pfizer and Moderna COVID-19 vaccines for all adults. Internal medicine physician Dr. Vivek Cherian joined Cheddar News to weigh in.
Neuroscientist Dr. Bankole Johnson joined Cheddar News to talk about the expectation of boosters for all U.S. adults and what the move would mean in the fight against the pandemic.
Deborah Sass, CO-CEO and Founding Partner of Space Hero, joins ChedHER to discuss how she's creating a global competition to send someone on a 10-day trip to space, her experience in the space industry without a background in STEM, and how she hopes to inspire younger generations of women.
A new report from Dr. Michael Worobey alleges that it is likely that COVID-19 originated from a raccoon dog at the Wuhan live animal market in China. While his report does not rule out the coronavirus could have escaped from a lab, Worobey's evidence points to a natural origin.
Jill and Carlo are back to cover the latest in the Rittenhouse trial, new information on the origins of Covid, return-to-office and more.
JOIN US FOR THE YOUTUBE WATCH PARTY @ 9aET: http://www.youtube.com/cheddarnow
Over the weekend, Russia fired a missile at one of its own satellites, triggering an explosion that launched thousands of pieces of shrapnel through space and forced the astronauts aboard the International Space Station to shelter in place. Senior Writer from Space.com Chelsea 'Foxanne' Gohd, joined Cheddar to discuss more.
Gerald Comissiong, CEO of Todos Medical, joins None of the Above to discuss why we're seeing surges of COVID-19 cases in Europe, the potential for a winter surge of COVID-19, the benefits of high vaccination rates in a community, and the coming COVID treatment pills.
Cognitive healthcare platform BrainCheck recently raised $10 million in a Series B round. The platform offers neurologists a new way to detect and care for brain disorders like Alzeheimer's, and brain injuries like concussions. BrainCheck CEO Yael Katz joined Cheddar News' Closing Bell to discuss.
